Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Vincent Dubesky

Physician Assistant Lancaster, PA Physician Assistant

NPI 1235878927 CMS profile 11370796

1808 Colonial Village Ln Ste 103, Lancaster, PA 17601

Open in the dashboard

General payments

$7,354

350 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vincent Dubesky of Lancaster, PA is reported in the CMS Open Payments database as having received $7,354 across 350 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,576 112
2024 General $2,455 126
2023 General $1,907 89
2022 General $416 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Dubesky
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Vincent Dubesky were reported at $2,576. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Vincent Dubesky Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $416 $155 $48–$522 $149
2023 $1,907 $167 $52–$557 $160
2024 $2,455 $178 $55–$600 $164
2025 $2,576 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. ITI, Inc. $1,073 52 payments
  2. Otsuka America Pharmaceutical, Inc. $978 48 payments
  3. Teva Pharmaceuticals USA, Inc. $882 32 payments
  4. AbbVie, Inc. $784 63 payments
  5. Neurocrine Biosciences, Inc. $590 18 payments
  6. Janssen Pharmaceuticals, Inc $535 17 payments
  7. Alkermes, Inc. $510 18 payments
  8. Lundbeck LLC $489 30 payments
  9. Axsome Therapeutics, Inc. $414 18 payments
  10. E.R. Squibb & Sons, L.L.C. $397 16 payments
  11. Other $702 38 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,045 345 payments
  2. Education $309 5 payments
Products named General payments · program years 2022–2025
  1. CAPLYTA $644 35 payments
  2. VRAYLAR $643 48 payments
  3. INGREZZA $590 18 payments
  4. REXULTI Psychiatry $525 25 payments
  5. LYBALVI Cns $510 18 payments
  6. ABILIFY MAINTENA $500 28 payments
  7. REXULTI Psychiatry $489 30 payments
  8. ABILIFY ASIMTUFII $453 23 payments
  9. LYBALVI Cns $448 15 payments
  10. UZEDY $447 23 payments
  11. Other $4,138 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 61 drugs

Part D claims

3,507

Median for Physician Assistant: 241

Drug cost

$549,915

Median for Physician Assistant: $4,110

Branded share of claims

24.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 99 $128,721
Abilify Maintena Aripiprazole Brand 35 $87,218
Latuda Lurasidone Hcl Brand 39 $74,289
Abilify Asimtufii Aripiprazole Brand 12 $63,893
Aristada Aripiprazole Lauroxil Brand 15 $51,791
Caplyta Lumateperone Tosylate Brand 12 $20,313
Rexulti Brexpiprazole Brand 12 $16,618
Lybalvi Olanzapine/Samidorphan Malate Brand 15 $13,528
Trintellix Vortioxetine Hydrobromide Brand 20 $13,197
Lurasidone Hcl Generic 52 $9,780

The 10 drugs with the highest cost, of 61 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$387 12 —
REXULTI
$301 12 —
VRAYLAR
$284 99 —
SPRAVATO
$245 — —
Qelbree
$233 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record